
Carole Imbert appointed as CFO of Vect-Horus
Ella Day | March 28, 2025 | Appointment | Biotech/start-up, Sales and Marketing | Pharmacy, Vect-Horus, appointment, biotech, cfo
Vect-Horus has announced it has appointed Carole Imbert as chief financial officer (CFO) and to its executive committee.
Vect-Horus is a biotechnology company that designs and develops molecular vectors allowing targeted delivery of therapeutic molecules and imaging agents to organs.
Imbert specialises in financial management and structuring. She previously served as head of financial and environmental social and governance (ESG) research for Arkéa Investment Services at Crédit Mutuel Arkéa. Imbert was also a financial analyst at Natexis, CPR and Exane, and head of investor relations and financial communication at both BIC and Eurazeo.
Imbert stated: “I am looking forward to strengthening the financial strategy of the company to ensure smooth continuity and support Vect-Horus’ mission to enhance transport of therapeutics across biological barriers.”
Alexandre Tokay, co-founder and CEO of Vect-Horus, commented on Imbert’s appointment: “We are thrilled to welcome Carole to our management team. Her extensive background in financial strategy and investor relations will be complementary to our existing skilled team, and an invaluable asset to drive our growth and secure a strong financial position to underpin development of our vectors…”
Ella Day
28/3/25
Related Content

Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …






